Attention Deficit Hyperactivity Disorder Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Stimulants, and Non-Stimulants); By Demographics; By Distribution Channel; By Region; Segment Forecast, 2023-2032

Attention Deficit Hyperactivity Disorder Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Stimulants, and Non-Stimulants); By Demographics; By Distribution Channel; By Region; Segment Forecast, 2023-2032

The global attention deficit hyperactivity disorder market size is expected to reach USD 32.14 billion by 2032, according to a new study by Polaris Market Research. The report “Attention Deficit Hyperactivity Disorder Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Stimulants, and Non-Stimulants); By Demographics; By Distribution Channel; By Region; Segment Forecast, 2023-2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The expansion of the worldwide attention deficit hyperactivity disorder (ADHD) treatment market is anticipated to be fueled by prominent firms specializing in research & development for the treatment of the condition. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. released the phase 3 clinical trials evaluating the effectiveness, safety, and tolerability of oral centanafadin for the treatment of adults with ADHD. Along with investigating centanafadine’s effects in young children with ADHD, the business also intends to consult with the US Food and Drug Administration about the following procedures.

Furthermore, according to a study published in February 2021 and titled “The incidence of adult attention-deficit hyperactivity disorder: A global critical appraisal and meta-analysis,” the pervasiveness of persistent adult ADHD was 2.6%, and the incidence of symptomatic adult ADHD was 6.7%, transforming to 139.8 Mn & 366.3 Mn affected adults worldwide, in 2020. The market is therefore likely to grow throughout the forecast period due to the growing burden of ADHD and the rising need for its treatment.

Additionally, medicine FDA approvals for attention deficit hyperactivity disorder are rising which is boosting the market growth over the forecast period. For instance, in July 2021, Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII’s prescription information was updated owing to FDA approval of a supplementary New Drug Application (sNDA), according to a statement from the Adlon Therapeutics.

Also, the establishment of a center of excellence to enhance diagnosis, treatment, and care in Southeast Asia will be supported by a collaboration between Siemens Healthcare HMI Group, which was established in February 2022. This collaboration advances the study and creation of brand-new ADHD medications in the Asia Pacific area. The market for treatments for ADHD has been adversely affected by the Covid-19 outbreak. involving the industries. Due to the fast urbanization and growing need for efficient use of space that already exists, the sector anticipates a lot of needs and demands following the pandemic.

Attention Deficit Hyperactivity Disorder Market Report Highlights

The hospital pharmacy segment is anticipated to grow at a high CAGR over the forecast period. As drug specialists, hospital pharmacists can help ADHD patients and their parents choose the right medications.

The adult segment accounted for largest revenue share due to the huge target population base and increased risk of acquiring focus hyperactivity disorder.

Asia-Pacific is expected to grow at a high CAGR over the projected period. The existence of major market participants and their strategic efforts to create and promote innovative patient-focused goods

The global players include Adlon Therapeutics, American Brivision, Cingulate Inc., Eli Lilly, Neos Therapeutics, Novartis AG, Noven Pharmaceuticals, Purdue Pharma, RespireRx Pharmaceuticals, Supernus Pharmaceuticals, Takeda Pharmaceutical, and Tris Pharma.

Polaris Market Research has segmented the Attention Deficit Hyperactivity Disorder market report based on drug type, distribution channel, demographics, and region:

Attention Deficit Hyperactivity Disorder, Drug Type Outlook (Revenue – USD Billion, 2019 – 2032)

Stimulants

Amphetamine

Methylphenidate

Lisdexamfetamine

Dexmethylphenidate

Non-stimulants

Atomoxetine

Guanfacine

Clonidine

Others

Attention Deficit Hyperactivity Disorder, Demographics Outlook (Revenue – USD Billion, 2019 – 2032)

Children (2 to 17 years of age)

Adults

Attention Deficit Hyperactivity Disorder, Distribution Channel Outlook (Revenue – USD Billion, 2019 – 2032)

Retail Pharmacy

Hospital Pharmacy

Attention Deficit Hyperactivity Disorder, Regional Outlook (Revenue – USD Billion, 2019 – 2032)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa